In our analysis we compared highly diverse MRD-test targets (specific cancer markers like BCR::ABL1, clonal markers such as IG/TCR rearrangements, aberrant cell phenotypes, circulating tumour DNA [ctDNA] etc.), assay types (MPFC, PCR, NGS etc.)and cancers, raising the question whether it is legitimate to consider these together. This evidence concerns the gene ABL1 and cancer.